Health Insurance · NYSE: ELV
Elevance Health earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 27 Jan 2027
Latest: Q3 2026
Elevance is pushing Carelon's integrated, value-based care model across its health plans and to outside clients, citing a 15% cut in avoidable admissions in its cancer program.
Elevance leaned on Carelon this quarter, linking pharmacy, behavioral health and home-based care to its health plans. Management says its cancer program cut avoidable admissions and its Elevate cost-management platform has flagged savings. Individual ACA enrollment held up better than expected after enhanced subsidies expired, with members shifting to lower-premium bronze plans. Medicaid, Medicare Advantage and employer risk membership kept shrinking. In commercial, several large employers returned to Anthem, drawn by integrated medical and pharmacy offerings.
Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗Official transcript (PDF) ↗
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $45.4B * |
| Q1 2025 | $48.9B |
| Q2 2025 | $49.8B |
| Q3 2025 | $50.7B |
| Q4 2025 | $49.7B * |
| Q1 2026 | $50.2B |
| Q2 2026 | $50.5B |
| Q3 2026 | $51.4B |
Data
| Q1 2025 | $9.61 |
| Q2 2025 | $7.72 |
| Q3 2025 | $5.32 |
| Q1 2026 | $8.00 |
| Q2 2026 | $6.71 |
| Q3 2026 | $6.27 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 1.5% |
| Q1 2025 | 6.5% |
| Q2 2025 | 4.9% |
| Q3 2025 | 2.6% |
| Q4 2025 | 0.6% |
| Q1 2026 | 4.2% |
| Q2 2026 | 3.5% |
| Q3 2026 | 2.5% |
Data
| Q4 2024 | $384.0M |
| Q1 2025 | $821.0M |
| Q2 2025 | $1.8B |
| Q3 2025 | $775.0M |
| Q4 2025 | -$209.0M |
| Q1 2026 | $4.1B |
| Q2 2026 | $1.6B |
| Q3 2026 | $1.0B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $45.4Bd | $48.9B | $49.8B | $50.7B | $49.7Bd | $50.2B | $50.5B | $51.4B |
| Operating income | $673.0Md | $3.2B | $2.4B | $1.3B | $309.0Md | $2.1B | $1.8B | $1.3B |
| Operating margin | 1.5% | 6.5% | 4.9% | 2.6% | 0.6% | 4.2% | 3.5% | 2.5% |
| Net income | $418.0Md | $2.2B | $1.7B | $1.2B | $547.0Md | $1.8B | $1.5B | $1.4B |
| Diluted EPS | — | $9.61 | $7.72 | $5.32 | — | $8.00 | $6.71 | $6.27 |
| Operating cash flow | $706.0Md | $1.0B | $2.1Bd | $1.1Bd | $84.0Md | $4.3B | $1.9Bd | $1.3Bd |
| Capital expenditure | $322.0Md | $196.0M | $267.0Md | $360.0Md | $293.0Md | $235.0M | $287.0Md | $267.0Md |
| Free cash flow | $384.0M | $821.0M | $1.8B | $775.0M | -$209.0M | $4.1B | $1.6B | $1.0B |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 21 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 15 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 22 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 6 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 21 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 17 Jul 202510-Q for the period ended 30 Jun 2025SEC ↗
- 22 Apr 202510-Q for the period ended 31 Mar 2025SEC ↗
- 20 Feb 202510-K for the period ended 31 Dec 2024SEC ↗